Last reviewed · How we verify
A Randomized, Controlled Trial of Melanoma Treatment: Comparison of Dendritic Cells Versus Montanide as Adjuvants to Stimulate Anti-tumor Immunity
In this study, a melanoma vaccine (5 melanoma peptides) is given with either Montanide or dendritic cells as adjuvants. This randomized trial will establish the safety of both vaccines and compare the 2 vaccine adjuvants in their efficacy to induce immune responses.
Details
| Lead sponsor | Dr. Nina Bhardwaj |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 50 |
| Start date | 2005-07 |
| Completion | 2009-04 |
Conditions
- Melanoma
Interventions
- KLH; Peptides; Dendritic Cells
- KLH, peptides plus Montanide
Primary outcomes
- Immunology — Examine whether DCs pulsed with candidate melanoma-specific peptides and KLH can boost CTL responses to melanoma antigens
Countries
United States